ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2744

Long-Term Remission in Severe Behcet’s Disease Following Withdrawal of Successful Anti-TNF Treatment

Petros P Sfikakis1, Aikaterini Arida1, Stylianos Panopoulos2, Kalliopi Fragkiadaki2, George Pentazos3, Katerina Laskari3, Maria Tektonidou1 and Nikos Markomichelakis2, 1First Department of Propaedeutic and Internal Medicine and Joint Rheumatology Program, National and Kapodistrian University of Athens Medical School, athens, Greece, 2First Department of Propaedeutic and Internal Medicine and Joint Rheumatology Program, National and Kapodistrian University of Athens Medical School, Athens, Greece, 3Rheumatology Unit, 1st Dept. of Propaedeutic Internal Medicine, Joined Academic Rheumatology Program, Athens University Medical School, Athens, Greece

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: anti-TNF therapy and remission, Behcet's syndrome, DMARDs

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 7, 2017

Title: Vasculitis Poster III: Other Vasculitis Syndromes

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Anti-TNF treatment has been shown to be effective in inducing complete remission in many Behcet’s disease (BD) patients with eye, large vessel, intestine and central nervous system involvement, but data on patients’ outcomes after their discontinuation are currently lacking. We examined whether remission of BD with severe vital organ involvement is maintained after withdrawal of successful anti-TNF treatment.

Methods:

In this retrospective longitudinal outcome study we examined the records of all patients with BD who have been followed up in our center at least once yearly since 2000. The final follow-up visit and review of flow-charts was conducted during the first trimester of 2017. Patients eligible for the study’s analysis were those who, a) achieved complete and sustained remission during long-term anti-TNF treatment given for refractory to conventional immunosuppressive therapy disease, b) discontinued anti-TNF treatment at some point, and, c) were followed-up at least 3 years after discontinuation. The study’s endpoint was the proportion of patients achieving complete remission of BD, sustained for at least 3 years after withdrawal of the anti-TNF agent.

Results: Of our BD cohort comprising 87 patients, 29 were eligible for analysis (median anti-TNF treatment of 2 years, IQR 1.1-2.0). Of them, 12 (41%) achieved the study’s end-point. The remaining patients relapsed within 1 year (median, IQR 0.6-1.5) after discontinuation. Re-treatment with anti-TNF was safe and effective in the long-term in 14/17 (82%); 4 of them have also achieved the study’s end-point, so far. Overall, 16/29 patients (55%) remain currently in complete remission lasting for a median of 6.5 years (IQR 5.5-8); 34% are any drug-free, all treated with anti-TNF mainly for sight-threatening disease, and 21% are on low-dose maintenance with azathioprine only, treated initially with anti-TNF for ocular (n=4), intestinal and central nervous system involvement. Notably, patients remaining in drug-free remission were younger (p<0.03) and had shorter (p<0.03) BD duration at anti-TNF treatment initiation than patients on azathioprine maintenance.

Conclusion:

Drug-free, long-term remission after withdrawal of successful anti-TNF treatment is feasible in patients with severe BD. Since an anti-TNF-induced ‘cure’ cannot be differentiated from a spontaneous remission by natural history, prospective studies should examine whether anti-TNF should be used first-line for remission induction in every patient with vital organ involvement.


Disclosure: P. P. Sfikakis, None; A. Arida, None; S. Panopoulos, None; K. Fragkiadaki, None; G. Pentazos, None; K. Laskari, None; M. Tektonidou, None; N. Markomichelakis, None.

To cite this abstract in AMA style:

Sfikakis PP, Arida A, Panopoulos S, Fragkiadaki K, Pentazos G, Laskari K, Tektonidou M, Markomichelakis N. Long-Term Remission in Severe Behcet’s Disease Following Withdrawal of Successful Anti-TNF Treatment [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/long-term-remission-in-severe-behcets-disease-following-withdrawal-of-successful-anti-tnf-treatment/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/long-term-remission-in-severe-behcets-disease-following-withdrawal-of-successful-anti-tnf-treatment/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology